Test Price
2,800 AED✅ Home Collection Available
DNAJC13 Gene PARK21 Parkinson Genetic Test | 2800 AED | DHA Licensed Laboratory in Dubai
Executive Summary & Core Metrics
- Accuracy Guarantee: 99.9% Diagnostic Sensitivity achieved via ISO 9001:2015 Certified NGS Processing (Cert: INT/EGQ/2509DA/3139).
- Premium Logistics: VIP Mobile Phlebotomy & Temperature-Controlled Cold-Chain Home Collection (Available daily from 8 AM to 11 PM).
- Clinical Guidance: Complimentary Telephonic Post-Test Clinical Guidance for result interpretation by qualified genetic counselors.
- Insurance: Direct Billing Verification available via WhatsApp at +971 54 548 8731.
- Test Price: 2800 AED inclusive of genetic counseling, NGS analysis, and comprehensive clinical reporting.
Test Overview & Methodology
The DNAJC13 Gene PARK21 Parkinson Genetic Test is a high-resolution molecular diagnostic assay utilizing Next-Generation Sequencing (NGS) to detect pathogenic variants in the DNAJC13 gene associated with autosomal-dominant late-onset Parkinson disease subtype PARK21. This test is clinically indicated for individuals with a family history of parkinsonism, atypical tremor disorders, or early-onset neurodegenerative symptoms requiring definitive molecular confirmation. Full gene coverage including all coding exons, intronic boundaries, and regulatory regions is achieved through a validated hybrid capture enrichment protocol.
| Feature | Our Test — DNAJC13 NGS | Closest Alternative — Single-Gene Sanger Sequencing |
|---|---|---|
| Technology | NGS (Next-Generation Sequencing) — Full Gene Coverage | Sanger Sequencing — Limited Exon-by-Exon Analysis |
| Diagnostic Sensitivity | 99.9% — Detects SNVs, Indels, and Copy Number Variants | ~85-90% — Misses Deep Intronic & Regulatory Variants |
| Turnaround Time | 3 to 4 Weeks (ISO-Accredited Laboratory) | 6 to 8 Weeks (Conventional Workflow) |
| Clinical Reporting | ACMG-Compliant Variant Classification + Genetic Counseling | Basic Variant Call — Limited Clinical Annotation |
| Sample Flexibility | Whole Blood / Extracted DNA / FTA Card Blood Spot | Whole Blood Only — Requires Venipuncture |
Physician Insight & Safety Protocols
Clinical Note from Lina Osama Zaki Quteineh (Consultant Medical Genetics | DHA Registration ID: 9294403):
"A confirmed pathogenic variant in DNAJC13 significantly elevates the lifetime risk of developing PARK21-linked parkinsonism, yet penetrance remains incomplete and age-dependent. This molecular finding must be interpreted within the full clinical context — incorporating neurological examination, DaTscan or cardiac MIBG scintigraphy when indicated, and a three-generation pedigree analysis. I counsel every patient to view this genetic result as a gateway to proactive neurological surveillance and personalized risk management, not as a deterministic verdict. The value lies in early detection and informed care planning, not in prediction alone."
⚠ Medication Safety Advisory
Do not discontinue, modify, or alter the dosage of any prescribed medication — including levodopa, dopamine agonists, MAO-B inhibitors, anticholinergics, or any neurological pharmacotherapy — without explicit consultation with your treating neurologist. Abrupt cessation of antiparkinsonian agents may precipitate severe withdrawal reactions, neuroleptic malignant-like syndrome, or acute motor decompensation. Always carry an updated medication list and report any adverse effects to your physician immediately.
⚠ Exclusion Criteria & Emergency Red Flags
Exclusion Criteria — Do Not Proceed if:
- Patient is under 18 years of age without a court-appointed legal guardian providing informed consent.
- Patient is unable to provide informed consent due to cognitive impairment and no legally authorized representative is available.
- Active chemotherapy within the last 14 days (may compromise DNA integrity and yield).
- Recent allogeneic bone marrow transplant or blood transfusion within 90 days (donor DNA interference risk).
- Known coagulopathy or severe thrombocytopenia (platelets < 30,000/µL) contraindicating venipuncture — request FTA Card collection instead.
🚨 Emergency Red Flags — Seek Immediate Medical Attention:
- Sudden onset of severe rigidity with hyperthermia (possible neuroleptic malignant syndrome).
- Acute confusion, hallucinations, or psychosis in a patient with known Parkinson diagnosis.
- Severe orthostatic hypotension with syncope or near-syncope episodes.
- Acute dysphagia with aspiration risk or respiratory distress.
- Suicidal ideation or severe depressive episode following genetic result disclosure.
Patient FAQ & Clinical Guidance
1. What does a positive DNAJC13 genetic test result actually mean for my Parkinson disease risk?
A positive DNAJC13 variant indicates you carry a pathogenic mutation associated with autosomal-dominant late-onset Parkinson disease subtype PARK21, which confers a significantly elevated lifetime risk of developing parkinsonism — but it is not a guarantee that you will develop the disease. The penetrance of DNAJC13 mutations is incomplete and age-dependent, meaning some carriers remain asymptomatic throughout their lives. Your result should be discussed with a neurologist specializing in movement disorders who can establish a personalized surveillance plan including periodic neurological examinations and, where indicated, advanced dopaminergic imaging to monitor for preclinical degeneration.
2. How long will it take to receive my results, and who will explain them to me?
Your complete NGS genetic report will be available within 3 to 4 weeks from sample receipt at our ISO 9001:2015 certified laboratory, and a complimentary post-test clinical guidance session with a certified genetic counselor is included. The report is structured in three tiers: a technical variant call with ACMG classification, a clinical correlation narrative contextualizing your result within the broader PARK21 literature, and actionable recommendations for neurological follow-up. You will receive a secure electronic copy via encrypted email, and a telephonic consultation will be scheduled within 48 hours of report release.
3. Can this test be performed on children or minors in the UAE?
Predictive genetic testing for adult-onset neurodegenerative conditions such as PARK21 is not permitted for asymptomatic minors under 18 years of age without explicit authorization from a court-appointed legal guardian and approval from a recognized Medical Ethics Committee. In cases with a strong family history of early-onset parkinsonism, referral to a specialized genetic counseling clinic is recommended to assess the clinical indication and obtain the necessary approvals under UAE federal law. The well-being of the minor and the principle of the child's right to an open future are paramount in all decisions.
UAE Regulatory & Data Privacy Adherence
✓ Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL): All patient genomic data, pedigree charts, and clinical records are processed, stored, and transmitted in full compliance with the UAE Personal Data Protection Law. Data encryption meets AES-256 standards; access is restricted to authorized laboratory personnel and the ordering clinician. No genomic data is shared with third parties, insurance providers, or external databases without explicit, revocable patient consent.
✓ Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields: Digital health data management, including electronic health records, telemedicine consultations, and remote genetic counseling sessions, complies with the UAE law governing ICT use in healthcare. Secure encrypted channels are used for all data transmission and patient communication.
✓ Federal Decree-Law No. 4 of 2016 on Medical Liability: Patient safety and informed consent processes adhere to the federal framework for medical liability, ensuring that every individual receives clear, documented information about the benefits, limitations, and implications of genetic testing before providing voluntary consent.
✓ ISO 9001:2015 Certification: Laboratory processing is accredited under ISO 9001:2015 (Certificate: INT/EGQ/2509DA/3139), guaranteeing standardized quality management systems across all pre-analytical, analytical, and post-analytical phases of genetic testing.
Clinical & Logistical Metadata
| Test Name | DNAJC13 Gene PARK21 Parkinson Genetic Test (NGS) |
| Price (AED) | 2,800 AED |
| Turnaround Time | 3 to 4 Weeks from sample receipt |
| Sample Type / Matrix | Whole Blood (EDTA Tube, 3-5 mL), Extracted DNA (min 1 µg at ≥20 ng/µL), or FTA Card Blood Spot (one fully saturated circle) |
| Methodology Used | Next-Generation Sequencing (NGS) — Full Gene Coverage including coding exons, intronic boundaries, and regulatory regions via hybrid capture enrichment |
| ICD-10-CM Code | G20 (Parkinson's disease) |
| LOINC Code | 95138-5 (Parkinson disease related gene sequencing) |
| DHA Facility License & Laboratory Address | DHA License: 1143 | Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE | DNA Labs UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians